Environmental Impact Assessment Report for Wanbande Pharmaceutical Group's Technology Upgrade Project

Date:

01 Mar,2021

Wanbande Pharmaceutical Group Co., Ltd.

New technical upgrade project to add annual production capacity of 20 tons of bifendate API, 980 tons of norfloxacin API, and 10 tons of traditional Chinese medicine extracts.

Environmental Impact Assessment Report

( Approval submission Draft

The full text is attached. Click to download

Wanbangde Pharmaceutical Group Co., Ltd. Announces Public Disclosure of the Environmental Impact Assessment for Its New Technical Renovation Project, which will add annual production capacity for 20 tons of Bifendate API, 980 tons of Norfloxacin API, and 10 tons of Traditional Chinese Medicine Extracts.

Wanbangde Pharmaceutical Group Officially Launches Its 2018 "Quality Month" Campaign

Related Recommendations

2024/12/16

Wandet Pharmaceutical Group's WP107 (Huperzine A Oral Solution) clinical trial application has been accepted by the U.S. FDA!

2024/12/16

Walking through the millennia-old cave complex, spreading the power of philanthropy | Wanbangde Pharmaceutical Group’s “Love Walk” event concludes successfully!

2024/11/29

Focusing on Change, Collaborating for Win-Win Results | Wanbangde Pharmaceutical Group Exhibits at the 89th National Pharmaceutical Fair

< 1...4 5 6...78 > proceed page

Website Development: China Enterprise Dynamics Taizhou

Business license